M Ventures

M Ventures, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany

“We admire entrepreneurs for their ability to turn science, technology and groundbreaking ideas into a product vision that could improve patient’s lives, disrupt industries or transform the way we live. We want to play our part in changing the world by provide these startups the exceptional support they need to make their vision a commercial success. We help our companies interface with our parent company, providing unique access to the broad expertise and infrastructure of a leading science and technology company.”

Jasper Bos
Senior Vice President and Managing Director M Ventures

More

2016/06/08

Merck KGaA, Darmstadt, Germany, Expands its Corporate Ventures Fund

Darmstadt, Germany, June 8, 2016 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced an increased commitment to its Corporate Ventures fund under the new Corporate Ventures fund roof (official name: M Ventures, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany). Four dedicated investment teams will focus on Healthcare, Life Science, Performance Materials and new businesses. The total volume of the newly set-up Corporate Ventures fund of Merck KGaA, Darmstadt, Germany, can reach up to € 300 million once fully invested, doubling the volume of the previous biopharma venture fund of € 150 million.

more

Funding early Innovation

We invest in early stage companies that develop the next generation products, technologies and applications to serve unmet medical needs and improve patient outcomes, as well as new solutions for science driven innovation.

More

Innovative Science.
Strategic Insights.

We invest in innovation to develop novel technologies and products to better serve future healthcare needs, solutions and services for R&D and production of drug therapies, as well as high tech chemicals for sophisticated applications.

More

Strategic Venture Capital.

We work closely with our portfolio companies to optimally position their assets towards strategic partnering.

More

Funding early Innovation

We invest in early stage companies that develop the next generation products, technologies and applications to serve unmet medical needs and improve patient outcomes, as well as new solutions for science driven innovation.

More

Innovative Science.
Strategic Insights.

We invest in innovation to develop novel technologies and products to better serve future healthcare needs, solutions and services for R&D and production of drug therapies, as well as high tech chemicals for sophisticated applications.

More

Strategic Venture Capital.

We work closely with our portfolio companies to optimally position their assets towards strategic partnering.

More